RE:RE:RE:RE:Medipharm Labs Big Win CADInvestor12 wrote: they did indicate B2B & Dronabinol impact .. taken directly from Q4 transcript ...
"we have seen renewed interest regarding B2B quality-focused manufacturing opportunity. Together, these deals could represent over $10 million in annual revenue potential." "The most exciting development in Germany in Q4 was the commercialization of our natural Dronabinol product. We believe that our natural GMP Dronabinol manufacturing and selling process is unique to MediPharm and is industry-leading in mitigating risk of quality and oxidization issues. The scale allows us to be competitive on current industry pricing while maintaining healthy margins. In 2024, Dronabinol will be a big part of our growth in German sales. In 2023, we sold just under $100,000 of this product, mostly for partner R&D. At this point, in 2024, we have already shipped this product to 3 customers and our sales and open orders are already over $1.5 million."
Certainly they made mention of those two, but it wasn't a strategic focus and neither really were on the radar up until that point. Sometimes things falling into your lap is a great thing, that said, until the drob business can be backed up by sustainable and concrete POs/long term supply agreements, that revenue kicker can go as quickly as it came. If Medipharm is the only game in town for drob, you'd think it wouldn't be hard to ink a couple of supply contracts with guaranteed volumes for say a 3-5 year term.